iTeos Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2025: USD -3.11

iTeos Therapeutics, Inc. EPS (Diluted) is USD -3.11 for the Trailing 12 Months (TTM) ending March 31, 2025. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • iTeos Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 0.28, a -96.47% change year over year.
  • iTeos Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 7.82, a -568.26% change year over year.
  • iTeos Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -1.67, a -16.08% change year over year.
Key Data
Date EPS (Diluted) Shares (Diluted, Weighted) Selling, General, and Administrative Expenses (SG&A) Research and Development (R&D) Expenses